At the semi-annual results meeting on September 9, Lianying Medical Chief Financial Officer Wang Jianbao analyzed in response to future revenue and profit growth issues. Looking ahead to 2027-2028, domestic equipment updates and high-end upgrades combined with the expansion of multiple overseas product lines, overall revenue is expected to maintain the current growth trend. The company's profits are disrupted by high R&D and overseas upfront investment. After eliminating phased factors such as exchange, the core profit growth rate will move closer to the revenue growth rate.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.